Dimensional Fund Advisors LP Acquires 29,300 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Dimensional Fund Advisors LP increased its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 3.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 771,607 shares of the company’s stock after buying an additional 29,300 shares during the quarter. Dimensional Fund Advisors LP owned about 1.07% of Kiniksa Pharmaceuticals worth $15,262,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of KNSA. KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $158,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after buying an additional 1,004 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after buying an additional 719 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth $258,000. Finally, New York State Common Retirement Fund increased its position in Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock valued at $302,000 after acquiring an additional 1,680 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 21,254 shares of the business’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $26.95, for a total value of $572,795.30. Following the sale, the chief financial officer now owns 27,009 shares in the company, valued at $727,892.55. The trade was a 44.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ross Moat sold 18,259 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the transaction, the insider now directly owns 9,415 shares of the company’s stock, valued at $191,030.35. This trade represents a 65.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 224,820 shares of company stock valued at $5,386,361 over the last ninety days. 54.57% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have issued reports on KNSA. Citigroup started coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price target for the company. Wedbush reaffirmed an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Finally, Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and an average price target of $38.80.

Kiniksa Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:KNSA opened at $26.72 on Friday. The stock has a 50 day moving average of $22.31 and a 200 day moving average of $21.38. The company has a market cap of $1.94 billion, a PE ratio of -190.84 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same period in the prior year, the business posted ($0.25) earnings per share. The company’s revenue was up 72.5% on a year-over-year basis. Equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.